Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.
The pharmacokinetics and safety of duloxetine were evaluated in a single-blind , placebo-controlled , escalating multiple-dose study in 12 healthy male subjects . In the treatment group ( n = 8) , duloxetine was administered orally at a starting dose of 20 mg twice daily ( bid ) and escalated at weekly intervals to 30 mg bid , then to 40 mg bid . The observed plasma concentration-time data at all three dose levels were adequately described by a one-compartment model with a first-order absorption rate constant . The mean oral clearance , apparent volume of distribution , and half-life values were 114 L/h ( range : 44 to 218 L/h ) , 1943 L ( range : 803 to 3531 L ) , and 12.5 h ( range : 9.2 to 19.1 h ) , respectively . Somnolence , nausea , and dry mouth were observed following the initial dose , but they resolved with continuing drug administration . Duloxetine was not associated with clinical ly significant changes in blood pressure ( BP ) or heart rate ( HR ) measured in the st and ing position . However , in recumbent position , small increases in systolic ( < or = 9 mmHg ) and diastolic ( < or = 5 mmHg ) BP and small decreases in HR ( < or = 6 beats/min ) were observed . Abrupt discontinuation of duloxetine was associated with a small increase in mean HR ( < or = 12 beats/min ) . In 3 subjects , abrupt discontinuation was also associated with transient sleep disturbance . No clinical ly important changes in electrocardiograms , cardiac intervals , clinical laboratory tests , and neurological functions were observed . These results indicate that duloxetine exhibits linear pharmacokinetics with respect to dose and duration of treatment and that a multiple oral dose regimen starting at 20 mg bid and gradually escalating up to 40 mg bid was generally well tolerated
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .